Haemonetics Corporation - 10-Q Summary
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, red cell, surgical, and plasma collection products. This report covers the third quarter and nine months ended December 29, 2001. The company operates as a single segment, with approximately 62% of revenues generated internationally.
Key Financial Metrics
| Metric (in thousands) | Q3 2001 | Q3 2000 | 9M 2001 | 9M 2000 |
|---|---|---|---|---|
| Net Revenues | $84,411 | $76,238 | $240,916 | $217,446 |
| Gross Profit | $41,235 | $39,019 | $117,347 | $105,886 |
| Operating Income | $2,806 | $10,967 | $25,292 | $4,322 |
| Net Income | $2,432 | $8,963 | $22,324 | $70 |
| Diluted EPS | $0.09 | $0.34 | $0.82 | $0.00 |
| Cash & Short-term Investments | $52,900 | N/A | N/A | N/A |
| Total Debt (Current + Long-term) | $75,357 | N/A | N/A | N/A |
Margin Analysis (9 Months): Gross margin remained stable at 48.7%. Operating margin improved significantly to 10.4% from 2.0% in the prior year, driven by the absence of large one-time acquisition charges in the current period.
Material Changes vs. Prior Period
- Revenue Growth: Nine-month revenues increased 10.8% ($23.5 million). On a constant currency basis, growth was 14.2%, driven by volume increases in Surgical (11.5%), Red Cells (43.9%), and Plasma (29.8%) disposables.
- Operating Expenses: Research and Development (R&D) expenses surged 82.9% year-over-year for the nine months, primarily due to a $10.0 million payment to acquire rights to a technology under development. Selling, General, and Administrative (SG&A) expenses increased 3.7%.
- One-Time Items: The prior year (9M 2000) included $18.6 million in In-Process Research and Development (IPR&D) charges and $4.6 million in other unusual charges related to the Transfusion Technologies acquisition. These were absent in the current period, significantly boosting operating income.
- Accounting Changes: The company adopted SFAS No. 133 (Derivatives) and SFAS No. 142 (Goodwill). The adoption of SFAS 133 resulted in a cumulative effect of change in accounting principle of $2.3 million (net of tax) included in net income for the nine months ended Dec 29, 2001. Goodwill amortization ceased under SFAS 142.
Outlook, Risks, and Management Commentary
- Product Pipeline: The Chairside Separator (CSS) project is 100% complete with an FDA 510K submission made in September 2001; sales expected upon approval. The Red Cell Collector (RCC) is 68% complete, with sales expected in fiscal 2004.
- Cost Savings: The "CORE" program generated approximately $3.1 million in cost savings for the nine months, with full-year fiscal 2002 savings estimated at $4.0 million.
- Liquidity: Working capital increased to $172.6 million. Cash flow from operations decreased to $15.1 million (from $34.2 million prior year) primarily due to a $13.3 million increase in inventory levels to support higher sales.
- Risks: Significant exposure to foreign exchange rates (62% of revenue is international). Risks include regulatory delays (FDA approvals), market acceptance of new products, and the impact of the September 11, 2001 events on the blood supply chain and red cell collection programs.
Investor Verification Checklist
- Verify the status and expected approval timeline of the CSS and RCC FDA submissions.
- Confirm the sustainability of the $10.0 million R&D technology acquisition payment and its impact on future earnings.
- Monitor inventory levels ($63.3 million) to ensure they align with sales velocity and do not indicate obsolescence.
- Assess the impact of foreign currency fluctuations on future margins, given the 62% international revenue mix.
- Review the timeline for the rollout of the Automated Cell Processing (ACP) 215 system and its contribution to Bloodbank revenue growth.